Apogee Therapeutics, Inc. (NASDAQ:APGE) Insider Sells $191,749.90 in Stock

Apogee Therapeutics, Inc. (NASDAQ:APGE) insider Carl Dambkowski sold 4,085 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $46.94, for a total value of $191,749.90. Following the sale, the insider now owns 255,348 shares of the company’s stock, valued at $11,986,035.12. The trade was a 1.57 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Carl Dambkowski also recently made the following trade(s):

• On Wednesday, December 11th, Carl Dambkowski sold 4,540 shares of Apogee Therapeutics stock. The stock was sold at an average price of $48.76, for a total transaction of $221,370.40.
• On Wednesday, December 4th, Carl Dambkowski sold 6,665 shares of Apogee Therapeutics stock. The shares were sold at an average price of $46.07, for a total transaction of $307,056.55.
• On Wednesday, November 6th, Carl Dambkowski sold 6,665 shares of Apogee Therapeutics stock. The shares were sold at an average price of $59.12, for a total transaction of $394,034.80.

Apogee Therapeutics Stock Performance

Shares of NASDAQ APGE opened at $47.77 on Monday. The business’s 50-day simple moving average is $49.13 and its 200-day simple moving average is $48.75. Apogee Therapeutics, Inc. has a 52 week low of $27.05 and a 52 week high of $72.29. The firm has a market cap of $2.15 billion, a price-to-earnings ratio of -19.74 and a beta of 2.26.

Institutional Investors Weigh In On Apogee Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. Allspring Global Investments Holdings LLC bought a new stake in shares of Apogee Therapeutics during the 2nd quarter worth $143,000. Principal Financial Group Inc. boosted its holdings in Apogee Therapeutics by 26.3% during the second quarter. Principal Financial Group Inc. now owns 6,442 shares of the company’s stock valued at $253,000 after acquiring an additional 1,340 shares during the period. Victory Capital Management Inc. boosted its holdings in Apogee Therapeutics by 56.8% during the second quarter. Victory Capital Management Inc. now owns 156,266 shares of the company’s stock valued at $6,149,000 after acquiring an additional 56,607 shares during the period. Arizona State Retirement System grew its position in shares of Apogee Therapeutics by 4.5% in the second quarter. Arizona State Retirement System now owns 5,993 shares of the company’s stock valued at $236,000 after purchasing an additional 258 shares during the last quarter. Finally, Los Angeles Capital Management LLC bought a new position in shares of Apogee Therapeutics in the second quarter worth about $272,000. Institutional investors own 79.04% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. Canaccord Genuity Group assumed coverage on Apogee Therapeutics in a report on Monday, November 25th. They set a “buy” rating and a $89.00 price objective for the company. Wedbush raised their price target on Apogee Therapeutics from $87.00 to $90.00 and gave the stock an “outperform” rating in a research note on Monday, December 2nd. Canaccord Genuity Group assumed coverage on Apogee Therapeutics in a report on Monday, November 25th. They set a “buy” rating and a $89.00 price target for the company. Finally, Guggenheim restated a “buy” rating on shares of Apogee Therapeutics in a report on Thursday, December 12th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $89.71.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.